These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

936 related articles for article (PubMed ID: 24334603)

  • 1. Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.
    Shi X; Chen X; Li X; Lan X; Zhao C; Liu S; Huang H; Liu N; Liao S; Song W; Zhou P; Wang S; Xu L; Wang X; Dou QP; Liu J
    Clin Cancer Res; 2014 Jan; 20(1):151-63. PubMed ID: 24334603
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pristimerin induces apoptosis in imatinib-resistant chronic myelogenous leukemia cells harboring T315I mutation by blocking NF-kappaB signaling and depleting Bcr-Abl.
    Lu Z; Jin Y; Chen C; Li J; Cao Q; Pan J
    Mol Cancer; 2010 May; 9():112. PubMed ID: 20482842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platinum pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via DUB inhibition-dependent caspase activation and Bcr-Abl downregulation.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Wang X; Shi X; Liu J
    Cell Death Dis; 2017 Jul; 8(7):e2913. PubMed ID: 28682311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nickel pyrithione induces apoptosis in chronic myeloid leukemia cells resistant to imatinib via both Bcr/Abl-dependent and Bcr/Abl-independent mechanisms.
    Lan X; Zhao C; Chen X; Zhang P; Zang D; Wu J; Chen J; Long H; Yang L; Huang H; Carter BZ; Wang X; Shi X; Liu J
    J Hematol Oncol; 2016 Nov; 9(1):129. PubMed ID: 27884201
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X; Jin Y; Cheng C; Zhang H; Zou W; Zheng Q; Lu Z; Chen Q; Lai Y; Pan J
    Clin Cancer Res; 2009 Mar; 15(5):1686-97. PubMed ID: 19240172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.
    Chen X; Shi X; Zhao C; Li X; Lan X; Liu S; Huang H; Liu N; Liao S; Zang D; Song W; Liu Q; Carter BZ; Dou QP; Wang X; Liu J
    Oncotarget; 2014 Oct; 5(19):9118-32. PubMed ID: 25193854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin derivative C817 inhibits proliferation of imatinib-resistant chronic myeloid leukemia cells with wild-type or mutant Bcr-Abl in vitro.
    Wu LX; Wu Y; Chen RJ; Liu Y; Huang LS; Lou LG; Zheng ZH; Chen YZ; Xu JH
    Acta Pharmacol Sin; 2014 Mar; 35(3):401-9. PubMed ID: 24487968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HS-543 induces apoptosis of Imatinib-resistant chronic myelogenous leukemia with T315I mutation.
    Kim SJ; Jung KH; Yan HH; Son MK; Fang Z; Ryu YL; Lee H; Lim JH; Suh JK; Kim J; Lee S; Hong S; Hong SS
    Oncotarget; 2015 Jan; 6(3):1507-18. PubMed ID: 25483100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dihydroartemisinin inhibits the Bcr/Abl oncogene at the mRNA level in chronic myeloid leukemia sensitive or resistant to imatinib.
    Lee J; Shen P; Zhang G; Wu X; Zhang X
    Biomed Pharmacother; 2013 Mar; 67(2):157-63. PubMed ID: 23201011
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrandrine citrate eliminates imatinib-resistant chronic myeloid leukemia cells in vitro and in vivo by inhibiting Bcr-Abl/β-catenin axis.
    Xu XH; Gan YC; Xu GB; Chen T; Zhou H; Tang JF; Gu Y; Xu F; Xie YY; Zhao XY; Xu RZ
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):867-74. PubMed ID: 23125079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pseudolaric acid B induces mitotic arrest and apoptosis in both imatinib-sensitive and -resistant chronic myeloid leukaemia cells.
    Jiang L; Wen C; He Q; Sun Y; Wang J; Lan X; Rohondia S; Dou QP; Shi X; Liu J
    Eur J Pharmacol; 2020 Jun; 876():173064. PubMed ID: 32179085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells.
    Kim JE; Yoon S; Choi BR; Kim KP; Cho YH; Jung W; Kim DW; Oh S; Kim DE
    Leukemia; 2013 Aug; 27(8):1650-8. PubMed ID: 23434731
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation.
    Lee YL; Chen CW; Liu FH; Huang YW; Huang HM
    PLoS One; 2013; 8(4):e61939. PubMed ID: 23613979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
    Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
    Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia.
    Golemovic M; Verstovsek S; Giles F; Cortes J; Manshouri T; Manley PW; Mestan J; Dugan M; Alland L; Griffin JD; Arlinghaus RB; Sun T; Kantarjian H; Beran M
    Clin Cancer Res; 2005 Jul; 11(13):4941-7. PubMed ID: 16000593
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthelmintic niclosamide suppresses transcription of BCR-ABL fusion oncogene via disabling Sp1 and induces apoptosis in imatinib-resistant CML cells harboring T315I mutant.
    Jin B; Wang C; Shen Y; Pan J
    Cell Death Dis; 2018 Jan; 9(2):68. PubMed ID: 29358661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
    Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
    Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proteasome inhibitor PS-341 inhibits growth and induces apoptosis in Bcr/Abl-positive cell lines sensitive and resistant to imatinib mesylate.
    Gatto S; Scappini B; Pham L; Onida F; Milella M; Ball G; Ricci C; Divoky V; Verstovsek S; Kantarjian HM; Keating MJ; Cortes-Franco JE; Beran M
    Haematologica; 2003 Aug; 88(8):853-63. PubMed ID: 12935973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.